US EditionGennova Biopharmaceuticals expands CEPI partnership for Nipah virus saRNA vaccine development - Express Pharma
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Gennova Biopharmaceuticals expands CEPI partnership for Nipah virus saRNA vaccine development - Express Pharma
Gennova Biopharmaceuticals, a subsidiary of Emcure Pharmaceuticals, is developing a self-amplifying mRNA (saRNA) vaccine for the Nipah virus. The project is backed by an expanded partnership with the Coalition for Epidemic Preparedness Innovations (CEPI), which has committed up to $13.38 million in funding. Gennova will collaborate with Houston Methodist Research Institute (HMRI), a CEPI partner based in the United States, to integrate artificia…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
